Effect of different concentrations of ropivacaine injection in the spinal canal on fever and prognosis in parturient women

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053761

Enrollment

Unknown

Registered

2021-11-29

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy,childbirth or puerperium

Interventions

Experimental group1:0.0625% ropivacaine

Experimental group2:0.075% ropivacaine

Experimental group3:0.1% ropivacaine

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Aged 20 to 40 years, height 150-175 cm, weight 50-80kg, ASAI or GRADE II single-term primipara (gestational age 37-41 weeks); 2.No obstetric complications and no contraindications for epidural puncture; 3.No history of allergy to experimental drugs; 4.Suitable for natural delivery and was willing to painless labor.

Exclusion criteria

Exclusion criteria: 1.Puerperas with body temperature > 37.5 degree before analgesia; 2.Have pregnancy complications, multiple pregnancy or parturient; 3.Women with contraindications of epidural space puncture; 4.Refused to join the study.

Design outcomes

Primary

Measure	Time frame
temperature;Interleukins-2;Interleukins-4;Interleukins-6;Interleukins-10;tumor necrosis factor-a;Interferon-?;Prostaglandin E2;	—

Secondary

Measure	Time frame
labor duration;neonatal Apgar score;	—

Countries

China

Contacts

Public ContactXiong Xiangqing

The First Affiliated Hospital of Wenzhou Medical University

xiangqingxiong@wmu.edu.cnK+86 13906631675

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026